Industry Insights

• 
  The Curtain Has Risen on the Competition for the First Generic Drug, so What Other Innovative Drugs in the Rare Disease Field Can We Look Forward to? Xiaobin
  January 23, 2025
  The CDE website shows Qilu Pharmaceutical applied for the marketing of nusinersen generic. Once controversial for high price, it treats SMA. Now many firms are involved, and SMA treatment progresses.
• 
  Outlook for the Development of Weight-loss Drugs in 2025 Krebs Qin
  January 23, 2025
  This article focuses on the challenges and opportunities for weight-loss drug development in 2025 after semaglutide and tirzepatide's market dominance. It covers GLP-1 drugs' potential in organ protection, new drug mechanisms, and pipeline products.
• 
  Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
  January 23, 2025
  ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.

• 
  Senolytics: The New Hope for Slowing Aging Nurah Ekhlaque
  March 04, 2025
  A Breakthrough in Slowing Aging & Longevity

• 
  InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
  February 18, 2025
• 
  TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines PR Newswire
  February 12, 2025
• 
  Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases PharmaSources
  October 15, 2024
  Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
  Mugwort, also known as fragrant mugwort or Artemisia argyi, is a herbaceous plant belonging to the Compositae family.
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024
• 
  Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives Xiaomichong
  July 19, 2024

• 
  20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
  December 13, 2024
  Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.